Moderating Effects in Randomized Trials—Interpreting the P Value, Confidence Intervals, and Hazard Ratios-Reference-Cited by-同舟云学术

Moderating Effects in Randomized Trials—Interpreting the P Value, Confidence Intervals, and Hazard Ratios

Published:2022-03 Issue:3 Volume:7 Page:371-374
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Agarwal Rajiv,Rifkin Brian

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Nephrology

Reference9 articles.

1. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019

2. Dapagliflozin in patients with chronic kidney disease;Heerspink;N Engl J Med,2020

3. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes;Bakris;N Engl J Med,2020

4. The kidney protective effects of the sodium–glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists;Provenzano;Kidney Int Rep,2022

5. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy;Rossing;Kidney Int Rep,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal Leadership Styles for Teacher Satisfaction: a Meta-analysis of the Correlation Between Leadership Styles and Teacher Job Satisfaction;Journal of the Knowledge Economy;2024-04-15

2. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review;Postgraduate Medicine;2024-02-16

3. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature;American Journal of Hypertension;2022-11-04

4. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE);Nephrology Dialysis Transplantation;2022-06-14

5. Letter Regarding “Moderating Effects in Randomized Trials—Interpreting the P Value, Confidence Intervals, and Hazard Ratios”;Kidney International Reports;2022-05